Pharmacotherapeutic Group: Quinolone antibacterials, fluoroquinolones. ATC Code: J01MA14.
Pharmacology: Pharmacodynamics: Mechanism of Action: Moxifloxacin is a fluoroquinolone antibiotic which contains an 8-methoxy group and has been termed an 8-methoxy fluoroquinolone. The 8-methoxy and 7-diazabicylo moieties on the quinolone nucleus of moxifloxacin appear to enhance activity against gram-positive bacteria and decrease selection of resistant mutants in gram-positive bacteria.
Moxifloxacin inhibits DNA synthesis in susceptible organisms via inhibition of the type II DNA topoisomerases (DNA gyrase, topoisomerase IV). Cross-resistance can occur between moxifloxacin and other fluoroquinolones, but some gram-positive bacteria resistant to other fluoroquinolones may be susceptible to moxifloxacin.
Pharmacokinetics: The drug has mean serum elimination half-life of 8.2-15.4 hours following IV administration.
Moxifloxacin is metabolized principally via sufate and glucuronide conjugation; the drug is not metabolized by and does not appear to affect the cytochrome P-450 (CYP) enzyme system.